These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1478338)

  • 21. Application of good manufacturing practice regulations to investigational biologic products.
    Goebel PW
    J Parenter Drug Assoc; 1980; 34(5):348-51. PubMed ID: 6905865
    [No Abstract]   [Full Text] [Related]  

  • 22. Making sure biologicals are safe.
    Hecht A
    FDA Consum; 1977; 11(6):21-6. PubMed ID: 10304996
    [No Abstract]   [Full Text] [Related]  

  • 23. Medical biotechnology: a brief historical survey.
    Bernon M; Bodelle J
    Bioprocess Technol; 1991; 13():xv-xxiii. PubMed ID: 1367128
    [No Abstract]   [Full Text] [Related]  

  • 24. ASTM lights the way for tissue engineered medical products standards: jump start for combination medical products that restore biological function of human tissues.
    Picciolo GL; Stocum DL
    Stand News; 2001 Jan; 29(1):30-5. PubMed ID: 11833591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Jun; 70(125):37861-2. PubMed ID: 15988855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The product development continuum: the evolution and application of the concept of comparability.
    Garnick RL
    Dev Biol (Basel); 2002; 109():3-8. PubMed ID: 12434907
    [No Abstract]   [Full Text] [Related]  

  • 27. The problem with the double-edged solution.
    Czap A
    Altern Med Rev; 2009 Jun; 14(2):96-8. PubMed ID: 19594219
    [No Abstract]   [Full Text] [Related]  

  • 28. Biosimilars legislation awakens data exclusivity debate.
    Hutson S
    Nat Med; 2009 Nov; 15(11):1242. PubMed ID: 19893548
    [No Abstract]   [Full Text] [Related]  

  • 29. Informed consent and living human cells.
    Maloney DM
    Hum Res Rep; 2002 Jul; 17(7):3. PubMed ID: 12731490
    [No Abstract]   [Full Text] [Related]  

  • 30. SuperGenerics: a better alternative for biogenerics.
    Charles SA
    Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
    [No Abstract]   [Full Text] [Related]  

  • 31. Biological products; blood specificity designators; technical amendments--FDA. Final rule; technical amendments.
    Fed Regist; 1994 May; 59(87):23636-7. PubMed ID: 10184096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Issues related to harmonization of testing requirements for viral safety.
    Hayakawa T
    Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Supplement to the points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology: nucleic acid characterization and genetic stability.
    Biologicals; 1993 Mar; 21(1):81-3. PubMed ID: 8217122
    [No Abstract]   [Full Text] [Related]  

  • 34. The new FDA combination products programme.
    Donawa M
    Med Device Technol; 2002 Oct; 13(8):25-8. PubMed ID: 12416330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adventitious agents from animal-derived raw materials and production systems.
    Hellman KB; Honstead JP; Vincent CK
    Dev Biol Stand; 1996; 88():231-4. PubMed ID: 9119142
    [No Abstract]   [Full Text] [Related]  

  • 36. Blood safety proposals.
    Oncology (Williston Park); 1994 Jun; 8(6):57-8. PubMed ID: 8074984
    [No Abstract]   [Full Text] [Related]  

  • 37. Reproductive toxicity testing of therapeutic biotechnology agents.
    Henck JW; Hilbish KG; Serabian MA; Cavagnaro JA; Hendrickx AG; Agnish ND; Kung AH; Mordenti J
    Teratology; 1996 Mar; 53(3):185-95. PubMed ID: 8761886
    [No Abstract]   [Full Text] [Related]  

  • 38. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Nov; 69(226):68611-88. PubMed ID: 15562555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
    Simek SL
    Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analyte-specific reagents.
    Press RD
    Mol Diagn; 1999 Mar; 4(1):71. PubMed ID: 10229777
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.